Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Jan;77(1):21-30.
doi: 10.1111/bcp.12102.

The hepatic cannabinoid 1 receptor as a modulator of hepatic energy state and food intake

Martin E Cooper  1 , Simon E Regnell
Affiliations
Review

The hepatic cannabinoid 1 receptor as a modulator of hepatic energy state and food intake

Martin E Cooper et al. Br J Clin Pharmacol. 2014 Jan.

Abstract

The cannabinoid 1 receptor (CB1R) has a well-established role in appetite regulation. Central CB1R antagonists, notably rimonabant, induced weight loss and improved the metabolic profile in obese individuals, but were discontinued due to psychiatric side-effects. The CB1R is also expressed peripherally, where its effects include promotion of liver fat accumulation, which consumes ATP. Type 2 diabetes in obese subjects is linked to excess liver fat, whilst there is a negative correlation between hepatic ATP content and insulin resistance. A decreased hepatic ATP/AMP ratio increases food intake by signals via the vagus nerve to the brain. The hepatic cannabinoid system is highly upregulated in obesity, and the effects of hepatic CB1R activation include increased activity of lipogenic and gluconeogenic transcription factors. Thus, blockade of hepatic CB1Rs could contribute significantly to the weight-reducing and insulin-sensitizing effects of CB1R antagonists. Additionally, upregulation of the hepatic CB1R may contribute to chronic liver inflammation, fibrosis and cirrhosis from causes including obesity, alcoholism and viral hepatitis. Peripheral CB1R antagonists induce weight loss and metabolic improvements in obese rodents; however, as there is evidence that hepatic CB1Rs are predominately intracellular, due to high intrinsic clearance, many drugs may not effectively block these receptors and therefore have limited efficacy. Hepatoselective CB1R antagonists may be effective at reducing hepatic steatosis, insulin resistance and bodyweight in obese, diabetic patients, with far fewer side-effects than first-generation CB1R antagonists. Additionally, such compounds may be effective in treating inflammatory liver disease, such as non-alcoholic steatohepatitis, reducing the likelihood of disease progression to cirrhosis or cancer.

Keywords: cannabinoid 1 receptor; diabetes; fatty liver; hepatic energy state; non-alcoholic steatohepatitis; obesity.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Central mediators of steatosis activated by CB1R. Green boxes indicate increased activity; red ones decreased activity. Abbreviations are as follows: ACC, acetyl-CoA carboxylase; AMPK, AMP-activated protein kinase; CB1R, cannabinoid 1 receptor; CPT1, carnitine palmitoyltransferase I; FAS, fatty acid synthase; LKB1, liver kinase B1; LXRα, Liver X receptor alpha; mTORC1, mammalian target of rapamycin complex 1; PKA, protein kinase A; SREBP-1c, sterol regulatory element-binding protein 1c
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Hardie DG, Hawley SA. AMP-activated protein kinase: the energy charge hypothesis revisited. Bioessays. 2001;23:1112–1119. - PubMed
    1. Friedman MI. Obesity and the hepatic control of feeding behavior. Drug News Perspect. 2007;20:573–578. - PubMed
    1. Allen MS, Bradford BJ, Oba M. The hepatic oxidation theory of the control of feed intake and its application to ruminants. J Anim Sci. 2009;87:3317–3334. - PubMed
    1. Koch JE, Ji H, Osbakken MD, Friedman MI. Temporal relationships between eating behavior and liver adenine nucleotides in rats treated with 2,5-AM. Am J Physiol. 1998;274:R610–617. - PubMed
    1. Rawson NE, Friedman MI. Phosphate loading prevents the decrease in ATP and increase in food intake produced by 2,5-anhydro-D-mannitol. Am J Physiol. 1994;266:R1792–1796. - PubMed

MeSH terms

Substances

LinkOut - more resources